Evidence map›Paper›PMID 41168330›Full record

ArticleScientific reports2025

STAT1 and m

Jia Wei, Xuan'er Zhao, Huiping Wang, Cong Wang, Xinyi Liu, Zimeng Shan, Yican Guo, Xumeng Gu, Renren Li, Zhansheng Zhu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Beyond mBiomedicines · 2026
    Review
  3. Ubiquitination and NOncology letters · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jia WeiLaboratory of Experimental and Clinical Pathology, Department of Pathology, School of Basic Medical Sciences, Xuzhou Medical University, Xuzhou, 221004, China.
Xuan'er ZhaoSchool of Anesthesiology, Xuzhou Medical University, Xuzhou, 221004, China.
Huiping WangDepartment of Genetics, School of Life Science, Xuzhou Medical University, Xuzhou, 221004, China.
Cong WangLaboratory of Experimental and Clinical Pathology, Department of Pathology, School of Basic Medical Sciences, Xuzhou Medical University, Xuzhou, 221004, China.
Xinyi LiuThe First School of Clinical Medicine, Xuzhou Medical University, Xuzhou, 221004, China.
Zimeng ShanThe Second School of Clinical Medicine, Xuzhou Medical University, Xuzhou, 221004, China.
Yican GuoSchool of Medical Imaging, Xuzhou Medical University, Xuzhou, 221004, China.
Xumeng GuSchool of Anesthesiology, Xuzhou Medical University, Xuzhou, 221004, China.
Renren LiCenter of Healthcare Management, The Affiliated Maternity and Child Health Care Hospital of Xuzhou Medical University, Xuzhou, 221009, China. RENRENLI2023@163.com.
Zhansheng ZhuLaboratory of Experimental and Clinical Pathology, Department of Pathology, School of Basic Medical Sciences, Xuzhou Medical University, Xuzhou, 221004, China. victorzhu2013@xzhmu.edu.cn.

Funding

the Key Research and Development Program of Xuzhou City KC22125the Key Research and Development Program of Xuzhou City KC22193Xuzhou Medical University Undergraduate Training Program for Innovation and Entrepreneurship 202410313040Y
6 · The paper itself

Abstract

Interleukin-15 receptor alpha (IL15RA) demonstrates critical regulatory function in oncogenesis and immunomodulation across various malignancies. However, the role of IL15RA in cancers, such as Clear Cell Renal Cell Carcinoma (ccRCC) remains unclear. Therefore, integrated pan-cancer analysis and mechanism investigation assays are essential for IL15RA-directed therapeutic strategy optimization in ccRCC. The comprehensive pan-cancer analysis reveals IL15RA as a plausible diagnostic and prognostic biomarker, as well as a promising immunotherapeutic target across various cancers, particularly ccRCC. IL15RA promotes ccRCC metastasis based on the data of the investigation. Mechanistically, STAT1 binds to IL15RA promoter region, thereby enhancing IL15RA mRNA expression, while METTL3 modulates RNA m

Indexed as

Carcinoma, Renal CellKidney NeoplasmsNF-kappa BSTAT1 Transcription FactorZinc Finger E-box-Binding Homeobox 1AnimalsBiomarkers, TumorCell Line, TumorGene Expression Regulation, NeoplasticHumansMethyltransferasesMiceNeoplasm MetastasisPrognosisPromoter Regions, GeneticSignal TransductionBiomarkers, TumorMethyltransferasesNF-kappa BSTAT1 protein, humanSTAT1 Transcription FactorZEB1 protein, humanZinc Finger E-box-Binding Homeobox 1Clear cell renal cell carcinomaIL15RAm6AMetastasisNF-κΒZEB1

Identifiers

PMID41168330
PMCPMC12575848

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.